Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

Study Identifier:
SRK-015-004
ClinicalTrials.gov Identifier:
NCT05626855
EudraCT Identifier:
N/A
EU CT Number:
N/A
Sponsor:
Scholar Rock, Inc.
Active, not recruiting

Study Details

Medical Condition
  • All Spinal Muscular Atrophies
  • Spinal Muscular Atrophy Type III
  • Spinal Muscular Atrophy Type II
Study Drug
  • Drug: Apitegromab
Date
Apr 2023 - Nov 2026
Phase 1
Phase 2
Phase 3
Phase 4
Patient Requirements
Sex: Female & Male
Age: 2+ years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Patients have completed the Phase 2 TOPAZ (Study SRK-015-002) trial or the Phase 3 SAPPHIRE (Study SRK-015-003) trial. (For TOPAZ, completed is defined as completion of Visit EC14 in Extension Period C or participating in TOPAZ at the time the trial is ended. For SAPPHIRE, completed is defined as completion of Visit 14 or participating in SAPPHIRE at the time the trial is ended)
  • Estimated life expectancy \>2 years from the Baseline Visit (Day 1)
  • Able to receive study drug infusions and provide blood samples through the use of a peripheral IV or a long-term IV access device that the patient has placed for reasons independent from the trial
  • Able to adhere to the requirements of the protocol, including travel to the trial site and completing all trial procedures and trial visits
  • Females of childbearing potential must have a negative pregnancy test at the Baseline Visit and agree to use at least 1 highly effective method of contraception throughout the trial and for 20 weeks after the last dose of apitegromab
Exclusion Criteria
  • Patient permanently discontinued study treatment during the feeder trial (i.e., TOPAZ or SAPPHIRE)
  • Nutritional status that was not stable over the past 6 months and is not anticipated to be stable throughout the trial or medical necessity for a gastric/nasogastric feeding tube, where the majority of feeds are given by this route, as assessed by the Investigator
  • Patient is currently enrolled in any investigational drug trial other than TOPAZ or SAPPHIRE
  • Prior history of severe hypersensitivity reaction or intolerance to SMN-targeted therapies
  • Prior history of severe hypersensitivity reaction or intolerance to apitegromab
  • Use of chronic daytime noninvasive ventilatory support for \>16 hours daily in the 2 weeks before dosing, or anticipated to regularly receive such daytime ventilator support chronically throughout the trial
  • Any acute or comorbid condition interfering with the well-being of the patient at the patient's last visit in TOPAZ or SAPPHIRE, (including active systemic infection, the need for acute treatment, or inpatient observation due to any reason). After resolution of the condition, the patient can be enrolled in the trial if they meet all the other eligibility criteria.
  • Pregnant or breastfeeding
  • Any other condition or clinically significant laboratory result or ECG value that, in the opinion of the Investigator, may compromise safety or compliance, would preclude the patient from successful completion of the trial, or interfere with the interpretation of the results

Protocol Summary

The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.

Trial Locations

Location
Status
Location
Phoenix Childrens Hospital
Phoenix, Arizona, United States, 85016
Status
N/A
Location
UCSD Altman Clinical and Translational Research
La Jolla, California, United States, 92037
Status
N/A
Location
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Status
N/A
Location
Stanford Neuroscience Health Center
Palo Alto, California, United States, 94304
Status
N/A
Location
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
Status
N/A
Location
Nemours Biomedical Research
Orlando, Florida, United States, 32827
Status
N/A
Go to page

Contact Cure SMA

User Information

If you have general questions regarding clinical trials or would like to be added to the Cure SMA mailing list to receive communications regarding future registries, studies, or clinical trials in SMA, please fill out the form below. Fields marked with an asterisk (*) are mandatory.

  • Disability Advocate who does not have SMA
  • I am a healthcare provider
  • I am a researcher
  • I have no direct connection to SMA
  • I have SMA
  • I lost a child to SMA
  • My child has SMA
  • Someone close to me has/had SMA
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • India
  • Ireland
  • Israel
  • Italy
  • Japan
  • Lebanon
  • Malaysia
  • Mexico
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Republic of Korea
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.